Scientific Publications

Thrombosis and Hemostasis Assays

The Advantages of Custom Thrombosis and Hemostasis Assays in Early Therapeutic Development

It is never too soon to start thinking about establishing an early-stage hematology testing paradigm to evaluate therapeutic candidates’ potential side effects. Join our Global Chief Scientific Officer and internationally recognized KOL in hematology, Lisa K. Jennings, as she shares the benefits of utilizing custom hematology-based assays in determining MOAs and pathways behind drug development across a range of therapeutic areas.

MLM Memphis in New England Journal of Medicine

Our Navigators are pleased to announce the publication of “Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers” in the latest edition of the New England Journal of Medicine.